

BC PHARMACARE NEWSLETTER

Edition 19-004

June 20, 2019



IN THIS EDITION

TI LETTER: EPINEPHRINE AUTO-INJECTORS	1
PHARMANET: DIRECTIONS FOR USE FIELD	1
SMOKING CESSATION PROGRAM PRODUCT CHANGES.....	2
BENEFITS	2



TI LETTER: EPINEPHRINE AUTO-INJECTORS

The latest [Therapeutics Initiative Letter](#) explores epinephrine auto-injectors for anaphylaxis in outpatient use, examining the evidence that underlies the use and summarizing the advice that healthcare providers can offer patients.

PHARMANET: DIRECTIONS FOR USE FIELD

The Directions for Use field in PharmaNet is intended to contain directions to the patient, as provided by a prescriber on a prescription. Occasionally a pharmacist may include other prescription specific information to ensure the patient understands these directions for safe medication administration, such as the physical description of the medication (e.g., blue and white capsule) or important auxiliary information (e.g., do not take with alcohol).

The Directions for Use field should not include any personal information, such as contact information for patients' relatives or caregivers. If this information needs to be included in prescription packaging, please use an alternate

Continued next page...

The PharmaCare Newsletter is published by the Pharmaceutical Services Division to provide information to British Columbia's health care providers.

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete. The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.



method to the Directions for Use field. PharmaNet data is often disclosed to other organizations, such as to professional colleges assessing appropriateness of care of their registrants, or via the Data Stewardship committee for program evaluation and clinical care research. When personal information is included in the Directions for Use field, the disclosure of PharmaNet data for research and evaluation purposes is significantly slowed, as any personal information must be redacted before the files are disclosed.

SMOKING CESSATION PROGRAM PRODUCT CHANGES

Effective June 10, 2019, Nicoderm® patches will have different Natural Product Numbers (NPNs) than the over-the-counter versions (see table below).

PharmaCare will cover both the current and new NPNs until September 30, 2019. After this date, only Nicoderm® patches with the new NPNs will be fully covered by PharmaCare's Smoking Cessation Program.

BRAND NAME	PRODUCT TYPE AND STRENGTH	PACK SIZE	CURRENT NPN	NEW NPN
Nicoderm® Step 1	Patch 21mg	7	02093146	80044515
Nicoderm® Step 2	Patch 14mg	7	02093138	80044503
Nicoderm® Step 3	Patch 7mg	7	02093111	80044518

BENEFITS

The following product has been added as a regular benefit under PharmaCare Plans B, C, F, and W, and Fair PharmaCare (Plan I). This product is also a regular benefit under PharmaCare Plans G and P.

EFFECTIVE DATE	May 28, 2019		
DRUG NAME	methadone (Metadol-D®)		
DIN	02244290*	STRENGTH AND FORM	10 mg/mL oral concentrate
PINs FOR OAT USE	DESCRIPTION		
67000005	with direct interaction		
67000007	delivery with direct interaction		
67000006	without direct interaction		
67000008	delivery without direct interaction		

* DIN is a non-benefit. Product must be dispensed using an [appropriate PIN](#) to be an eligible benefit under any plan.